<DOC>
	<DOCNO>NCT01461759</DOCNO>
	<brief_summary>The purpose study treat advance recurrent endometrial cancer , paclitaxel-containing regimen prefer chemotherapeutic regimen select physician . Docetaxel may similar efficacy favorable treatment related toxicity profile test epithelial ovarian cancer trial . Therefore , investigator aim evaluate efficacy safety docetaxel plus cisplatin patient advance recurrent endometrial cancer .</brief_summary>
	<brief_title>Efficacy Study Chemotherapy Treat Advanced Recurrent Endometrial Cancer</brief_title>
	<detailed_description />
	<mesh_term>Endometrial Neoplasms</mesh_term>
	<mesh_term>Docetaxel</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<criteria>Histologically confirm chemotherapy naïve endometrial cancer One follow histology Endometrioid , UPSC , CCCa , squamous , adenosquamous , mixed FIGO stage IVb recurrent endometrial cancer ( incurable surgery and/or RT ) At least one measurable lesion RECIST CT ECOG PS : 02 Age : 2075 Adequate organ function BM : ANC≥1,000/mm3 , Plt≥100X103/mm3 Kidney : Creatinine &lt; 1.25 × UNL이고 , GFR ≥ 60 Liver : AST , ALT &lt; 3×UNL , T bil &lt; 1.5 mg/ mm3 Informed Consent Contraception study period Previous chemotherapy RT , hormone therapy , immunotherapy within 1 month Other malignant disease Uncontrolled medical disease Infection require antibiotic Symptomatic CHF , RF , Angina , Arrhythmia , etc . Neurosis psychosis Pregnancy , breastfeed Etc .</criteria>
	<gender>Female</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>October 2011</verification_date>
</DOC>